Linezolid update: Stable in vitro activity following more than a decade of clinical use and summary of associated resistance mechanisms

Drug Resistance Updates

Volumn 17, Issue 1-2, 2014, Pages 1-12

  Mendes, Rodrigo E ^a   Deshpande, Lalitagauri M ^a   Jones, Ronald N ^a,b  

^a JMI LABORATORIES   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

LEADER; Linezolid; Oxazolidinones; Resistance; Surveillance; ZAAPS

Indexed keywords

LINEZOLID; RADEZOLID; RNA 23S; TEDIZOLID; ACETAMIDE DERIVATIVE; ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; OXAZOLIDINONE DERIVATIVE; RIBOSOMAL PROTEIN L3; RIBOSOMAL PROTEIN L4; RIBOSOME PROTEIN; TETRAZOLE DERIVATIVE;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; ENTEROCOCCUS FAECALIS; FOOD AND DRUG ADMINISTRATION; GRAM POSITIVE BACTERIUM; HUMAN; IN VITRO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; PRIORITY JOURNAL; REVIEW; UNITED STATES; DRUG APPROVAL; DRUG EFFECTS; GENETICS; GRAM-POSITIVE BACTERIAL INFECTIONS; GROWTH, DEVELOPMENT AND AGING; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MUTATION;

ACETAMIDES; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; DRUG APPROVAL; DRUG RESISTANCE, BACTERIAL; GRAM-POSITIVE BACTERIA; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS; MUTATION; OXAZOLIDINONES; RIBOSOMAL PROTEINS; RNA, RIBOSOMAL, 23S; TETRAZOLES;

EID: 84902533691     PISSN: 13687646     EISSN: 15322084     Source Type: Journal    
DOI: 10.1016/j.drup.2014.04.002     Document Type: Review

References (134)

1. T.R. Anderegg, H.S. Sader, T.R. Fritsche, J.E. Ross, and R.N. Jones Trends in linezolid susceptibility patterns: report from the 2002-2003 worldwide Zyvox Annual Appraisal of Potency and Spectrum (ZAAPS) Program Int. J. Antimicrob. Agents 26 2005 13 21
2. G.C. Atkinson, L.H. Hansen, T. Tenson, A. Rasmussen, F. Kirpekar, and B. Vester Distinction between the Cfr methyltransferase conferring antibiotic resistance and the housekeeping RlmN methyltransferase Antimicrob. Agents Chemother. 57 2013 4019 4026
3. C. Auckland, L. Teare, F. Cooke, M.E. Kaufmann, M. Warner, G. Jones, K. Bamford, H. Ayles, and A.P. Johnson Linezolid-resistant enterococci: report of the first isolates in the United Kingdom J. Antimicrob. Chemother. 50 2002 743 746
4. C.H. Ballow, D.J. Biedenbach, F. Rossi, and R.N. Jones Multicenter assessment of the linezolid spectrum and activity using the disk diffusion and Etest methods: report of the Zyvox(R) Antimicrobial Potency Study in Latin America (LA-ZAPS) Braz. J. Infect. Dis. 6 2002 100 109
5. C.H. Ballow, R.N. Jones, and D.J. Biedenbach A multicenter evaluation of linezolid antimicrobial activity in North America Diagn. Microbiol. Infect. Dis. 43 2002 75 83
6. E. Baos, F.J. Candel, P. Merino, I. Pena, and J.J. Picazo Characterization and monitoring of linezolid-resistant clinical isolates of Staphylococcus epidermidis in an intensive care unit 4 years after an outbreak of infection by cfr-mediated linezolid-resistant Staphylococcus aureus Diagn. Microbiol. Infect. Dis. 76 2013 325 329
7. P. Beckert, D. Hillemann, T.A. Kohl, J. Kalinowski, E. Richter, S. Niemann, and S. Feuerriegel rplC T460C identified as a dominant mutation in linezolid-resistant Mycobacterium tuberculosis strains Antimicrob. Agents Chemother. 56 2012 2743 2745
8. J.M. Bell, J.D. Turnidge, C.H. Ballow, and R.N. Jones Multicentre evaluation of the in vitro activity of linezolid in the Western Pacific J. Antimicrob. Chemother. 51 2003 339 345
9. D.J. Biedenbach, and R.N. Jones Disk diffusion test interpretive criteria and quality control recommendations for testing linezolid (U-100766) and eperezolid (U-100592) with commercially prepared reagents J. Clin. Microbiol. 35 1997 3198 3202
10. D.J. Biedenbach, and R.N. Jones In vitro activity of linezolid (U-100766) against Haemophilus influenzae measured by three different susceptibility testing methods Diagn. Microbiol. Infect. Dis. 39 2001 49 53
11. D.J. Biedenbach, and R.N. Jones Revision of linezolid disk diffusion quality control guidelines for testing Staphylococcus aureus ATCC, 25923. An independent seven-laboratory trial Clin. Microbiol. Infect. 9 2003 1035 1037
12. D.S. Billal, J. Feng, P. Leprohon, D. Legare, and M. Ouellette Whole genome analysis of linezolid resistance in Streptococcus pneumoniae reveals resistance and compensatory mutations BMC Genomics 12 2011 512
13. A. Bock, F. Turnowsky, and G. Hogenauer Tiamulin resistance mutations in Escherichia coli J. Bacteriol. 151 1982 1253 1260
14. A. Bolmstrom, C.H. Ballow, A. Qwarnstrom, D.J. Biedenbach, and R.N. Jones Multicentre assessment of linezolid antimicrobial activity and spectrum in Europe: report from the Zyvox antimicrobial potency study (ZAPS-Europe) Clin. Microbiol. Infect. 8 2002 791 800
15. H. Bonilla, M.D. Huband, J. Seidel, H. Schmidt, M. Lescoe, S.P. McCurdy, M.M. Lemmon, L.A. Brennan, A. Tait-Kamradt, L. Puzniak, and J.P. Quinn Multicity outbreak of linezolid-resistant Staphylococcus epidermidis associated with clonal spread of a cfr-containing strain Clin. Infect. Dis. 51 2010 796 800
16. J. Bosling, S.M. Poulsen, B. Vester, and K.S. Long Resistance to the peptidyl transferase inhibitor tiamulin caused by mutation of ribosomal protein L3 Antimicrob. Agents Chemother. 47 2003 2892 2896
17. B. Bozdogan, and P.C. Appelbaum Oxazolidinones: activity, mode of action, and mechanism of resistance Int. J. Antimicrob. Agents 23 2004 113 119
18. J.C. Cai, Y.Y. Hu, R. Zhang, H.W. Zhou, and G.X. Chen Linezolid-resistant clinical isolates of meticillin-resistant coagulase-negative staphylococci and Enterococcus faecium from China J. Med. Microbiol. 61 2012 1568 1573
19. H. Chen, W. Wu, M. Ni, Y. Liu, J. Zhang, F. Xia, W. He, Q. Wang, Z. Wang, B. Cao, and H. Wang Linezolid-resistant clinical isolates of enterococci and Staphylococcus cohnii from a multicentre study in China: molecular epidemiology and resistance mechanisms Int. J. Antimicrob. Agents 42 2013 317 321
20. Clinical and Laboratory Standards Institute CLSI Subcommittee on Antimicrobial Testing Meeting Minutes, January 2006 2006 Clinical and Laboratory Standards Institute Miami, FL, USA
21. Clinical and Laboratory Standards Institute CLSI Subcommittee on Antimicrobial Susceptibility Testing Meeting Minutes, January 2012 2012 Clinical and Laboratory Standards Institute Tempe, AZ, USA
22. Clinical and Laboratory Standards Institute M07-A9. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically; Approved Standard 9th edition 2012 Clinical and Laboratory Standards Institute Wayne, PA, USA
23. Clinical and Laboratory Standards Institute M100-S23. Performance Standards for Antimicrobial Susceptibility Testing: 23rd Informational Supplement 2013 Clinical and Laboratory Standards Institute Wayne, PA, USA
24. Clinical and Laboratory Standards Institute M07-A10. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically; Approved Standard 10th ed. 2014 Clinical and Laboratory Standards Institute Wayne, PA, USA
25. J.R. Colca, W.G. McDonald, D.J. Waldon, L.M. Thomasco, R.C. Gadwood, E.T. Lund, G.S. Cavey, W.R. Mathews, L.D. Adams, E.T. Cecil, J.D. Pearson, J.H. Bock, J.E. Mott, D.L. Shinabarger, L. Xiong, and A.S. Mankin Cross-linking in the living cell locates the site of action of oxazolidinone antibiotics J. Biol. Chem. 278 2003 21972 21979
26. L. Cui, Y. Wang, Y. Li, T. He, S. Schwarz, Y. Ding, J. Shen, and Y. Lv Cfr-mediated linezolid-resistance among methicillin-resistant coagulase-negative Staphylococci from infections of humans PLoS ONE 8 2013 e57096
27. L. Dai, C.M. Wu, M.G. Wang, Y. Wang, Y. Wang, S.Y. Huang, L.N. Xia, B.B. Li, and J.Z. Shen First report of the multidrug resistance gene cfr and the phenicol resistance gene fexA in a Bacillus strain from swine feces Antimicrob. Agents Chemother. 54 2010 3953 3955
28. L.M. de Almeida, M.R. de Araujo, A.G. Sacramento, M. Pavez, A.G. de Souza, F. Rodrigues, A.C. Gales, N. Lincopan, J.L. Sampaio, and E.M. Mamizuka Linezolid resistance in Brazilian Staphylococcus hominis strains is associated with L3 and 23S rRNA ribosomal mutations Antimicrob. Agents Chemother. 57 2013 4082 4083
29. L.M. Deshpande, S. Vega, J.E. Ross, R.N. Jones, and R.N. Mendes Detection of plasmid-encoded Cfr in clinical isolates of Enterococcus faecalis from Panama City: report from the SENTRY Antimicrobial Surveillance Programme Abstract P1405. 23rd ECCMID April 27-30, 2013, Berlin, Germany 2013
30. L. Diaz, P. Kiratisin, R. Mendes, D. Panesso, K.V. Singh, and C.A. Arias Transferable plasmid-mediated resistance to linezolid due to cfr in a human clinical isolate of Enterococcus faecalis Antimicrob. Agents Chemother. 56 2012 3917 3922
31. D.C. Draghi, D.J. Sheehan, P. Hogan, and D.F. Sahm In vitro activity of linezolid against key Gram-positive organisms isolated in the United States: results of the LEADER 2004 surveillance program Antimicrob. Agents Chemother. 49 2005 5024 5032
32. A. Endimiani, M. Blackford, E.C. Dasenbrook, M.D. Reed, S. Bajaksouszian, A.M. Hujer, S.D. Rudin, K.M. Hujer, V. Perreten, L.B. Rice, M.R. Jacobs, M.W. Konstan, and R.A. Bonomo Emergence of linezolid-resistant Staphylococcus aureus after prolonged treatment of cystic fibrosis patients in Cleveland, Ohio Antimicrob. Agents Chemother. 55 2011 1684 1692
33. EUCAST Breakpoint tables for interpretation of MICs and zone diameters. Version 3.1, February 2013. 2013 available at http://www.eucast.org/clinical- breakpoints/ (accessed August 2013)
34. D.J. Farrell, R.E. Mendes, J.E. Ross, and R.N. Jones Linezolid surveillance program results for 2008 (LEADER Program for 2008) Diagn. Microbiol. Infect. Dis. 65 2009 392 403
35. D.J. Farrell, R.E. Mendes, J.E. Ross, H.S. Sader, and R.N. Jones LEADER Program results for 2009: an activity and spectrum analysis of linezolid using 6,414 clinical isolates from the United States (56 Medical Centers) Antimicrob. Agents Chemother. 55 2011 3684 3690
36. A.T. Febler, N. Calvo, N. Gutierrez, J.L. Munoz Bellido, M. Fajardo, E. Garduno, S. Monecke, R. Ehricht, K. Kadlec, and S. Schwarz Cfr-mediated linezolid resistance in methicillin-resistant Staphylococcus aureus and Staphylococcus haemolyticus associated with clinical infections in humans: two case reports J. Antimicrob. Chemother. 69 2013 268 270
37. M. Fines, and R. Leclercq Activity of linezolid against Gram-positive cocci possessing genes conferring resistance to protein synthesis inhibitors J. Antimicrob. Chemother. 45 2000 797 802
38. R.K. Flamm, D.J. Farrell, R.E. Mendes, J.E. Ross, H.S. Sader, and R.N. Jones LEADER surveillance program results for 2010: an activity and spectrum analysis of linezolid using 6801 clinical isolates from the United States (61 medical centers) Diagn. Microbiol. Infect. Dis. 74 2012 54 61
39. R.K. Flamm, D.J. Farrell, R.E. Mendes, J.E. Ross, H.S. Sader, and R.N. Jones ZAAPS program results for 2010: an activity and spectrum analysis of linezolid using clinical isolates from 75 medical centers in 24 countries J. Chemother. 24 2012 328 337
40. R.K. Flamm, R.E. Mendes, J.E. Ross, H.S. Sader, and R.N. Jones Linezolid surveillance results for the United States: LEADER Surveillance Program 2011 Antimicrob. Agents Chemother. 57 2013 1077 1081
41. R.K. Flamm, R.E. Mendes, J.E. Ross, H.S. Sader, and R.N. Jones An international activity and spectrum analysis of linezolid: ZAAPS program results for 2011 Diagn. Microbiol. Infect. Dis. 76 2013 206 213
42. J.L. Floyd, K.P. Smith, S.H. Kumar, J.T. Floyd, and M.F. Varela LmrS is a multidrug efflux pump of the major facilitator superfamily from Staphylococcus aureus Antimicrob. Agents Chemother. 54 2010 5406 5412
43. A.C. Gales, H.S. Sader, S.S. Andrade, L. Lutz, A. Machado, and A.L. Barth Emergence of linezolid-resistant Staphylococcus aureus during treatment of pulmonary infection in a patient with cystic fibrosis Int. J. Antimicrob. Agents 27 2006 300 302
44. A.C. Gales, L.M. Deshpande, R.N. Jones, A.G. De Souza, A.C. Pignatari, and R.E. Mendes Fatal pneumonia due to methicillin-susceptible Staphylococcus aureus ST398/t034 carrying cfr and erm(B) genes: first report in Brazil J. Antimicrob. Chemother. 2014 (in press)
45. D.R. Gentry, S.F. Rittenhouse, L. McCloskey, and D.J. Holmes Stepwise exposure of Staphylococcus aureus to pleuromutilins is associated with stepwise acquisition of mutations in rplC and minimally affects susceptibility to retapamulin Antimicrob. Agents Chemother. 51 2007 2048 2052
46. E.R. Gopegui, C. Juan, L. Zamorano, J.L. Perez, and A. Oliver Transferable multidrug resistance plasmid carrying cfr associated with tet(L), ant(4′)-Ia, and dfrK genes from a clinical methicillin-resistant Staphylococcus aureus ST125 strain Antimicrob. Agents Chemother. 56 2012 2139 2142
47. I.M. Gould, and A.M. Bal New antibiotic agents in the pipeline and how they can help overcome microbial resistance Virulence 4 2013 185 191
48. L.H. Hansen, M.H. Planellas, K.S. Long, and B. Vester The order Bacillales hosts functional homologs of the worrisome cfr antibiotic resistance gene Antimicrob. Agents Chemother. 56 2012 3563 3567
49. A.P. Johnson, M. Warner, and D.M. Livermore Activity of linezolid against multi-resistant Gram-positive bacteria from diverse hospitals in the United Kingdom J. Antimicrob. Chemother. 45 2000 225 230
50. A.P. Johnson, L. Tysall, M.V. Stockdale, N. Woodford, M.E. Kaufmann, M. Warner, D.M. Livermore, F. Asboth, and F.J. Allerberger Emerging linezolid-resistant Enterococcus faecalis and Enterococcus faecium isolated from two Austrian patients in the same intensive care unit Eur. J. Clin. Microbiol. Infect. Dis. 21 2002 751 754
51. R.N. Jones, D.M. Johnson, and M.E. Erwin In vitro antimicrobial activities and spectra of U-100592 and U-100766, two novel fluorinated oxazolidinones Antimicrob. Agents Chemother. 40 1996 720 726
52. R.N. Jones, C.H. Ballow, and D.J. Biedenbach Multi-laboratory assessment of the linezolid spectrum of activity using the Kirby-Bauer disk diffusion method: report of the Zyvox Antimicrobial Potency Study (ZAPS) in the United States Diagn. Microbiol. Infect. Dis. 40 2001 59 66
53. R.N. Jones, J.E. Ross, T.R. Fritsche, and H.S. Sader Oxazolidinone susceptibility patterns in 2004: report from the Zyvox® Annual Appraisal of Potency and Spectrum (ZAAPS) Program assessing isolates from 16 nations J. Antimicrob. Chemother. 57 2006 279 287
54. R.N. Jones, T.R. Fritsche, H.S. Sader, and J.E. Ross LEADER surveillance program results for 2006: an activity and spectrum analysis of linezolid using clinical isolates from the United States (50 medical centers) Diagn. Microbiol. Infect. Dis. 59 2007 309 317
55. R.N. Jones, T.R. Fritsche, H.S. Sader, and J.E. Ross Zyvox® Annual Appraisal of Potency and Spectrum Program results for 2006: an activity and spectrum analysis of linezolid using clinical isolates from 16 countries Diagn. Microbiol. Infect. Dis. 59 2007 199 209
56. R.N. Jones, J.E. Ross, M. Castanheira, and R.E. Mendes United States resistance surveillance results for linezolid (LEADER Program for 2007) Diagn. Microbiol. Infect. Dis. 62 2008 416 426
57. R.N. Jones, S. Kohno, Y. Ono, J.E. Ross, and K. Yanagihara ZAAPS International Surveillance Program (2007) for linezolid resistance: results from 5591 Gram-positive clinical isolates in 23 countries Diagn. Microbiol. Infect. Dis. 64 2009 191 201
58. R.N. Jones, R.E. Mendes, D.J. Farrell, H.S. Sader, and J.E. Ross Summary of 2009 oxazolidinone resistance (R) surveillance studies worldwide (LEADER and ZAAPS Programs) Abstract 263. 48th IDSA, October 21-24, 2010 Vancouver, B.C., Canada 2010
59. C. Kehrenberg, and S. Schwarz Distribution of florfenicol resistance genes fexA and cfr among chloramphenicol-resistant Staphylococcus spp. isolates Antimicrob. Agents Chemother. 50 2006 1156 1163
60. C. Kehrenberg, K.K. Ojo, and S. Schwarz Nucleotide sequence and organization of the multiresistance plasmid pSCFS1 from Staphylococcus sciuri J. Antimicrob. Chemother. 54 2004 936 939
61. C. Kehrenberg, C. Cuny, B. Strommenger, S. Schwarz, and W. Witte Methicillin-resistant and -susceptible Staphylococcus aureus strains of clonal lineages ST398 and ST9 from swine carry the multidrug resistance gene cfr Antimicrob. Agents Chemother. 53 2009 779 781
62. K. Kosowska-Shick, C. Clark, K. Credito, P. McGhee, B. Dewasse, T. Bogdanovich, and P.C. Appelbaum Single- and multistep resistance selection studies on the activity of retapamulin compared to other agents against Staphylococcus aureus and Streptococcus pyogenes Antimicrob. Agents Chemother. 50 2006 765 769
63. K. Kosowska-Shick, K.G. Julian, P.L. McGhee, P.C. Appelbaum, and C.J. Whitener Molecular and epidemiologic characteristics of linezolid-resistant coagulase-negative staphylococci at a tertiary care hospital Diagn. Microbiol. Infect. Dis. 68 2010 34 39
64. J.M. LaMarre, J.B. Locke, K.J. Shaw, and A.S. Mankin Low fitness cost of the multidrug resistance gene cfr Antimicrob. Agents Chemother. 55 2011 3714 3719
65. J. LaMarre, R.E. Mendes, T. Szal, S. Schwarz, R.N. Jones, and A.S. Mankin The genetic environment of the cfr gene and the presence of other mechanisms account for the very high linezolid resistance of the Staphylococcus epidermidis isolate 426-3147L Antimicrob. Agents Chemother. 57 2013 1173 1179
66. K.L. Leach, S.M. Swaney, J.R. Colca, W.G. McDonald, J.R. Blinn, L.M. Thomasco, R.C. Gadwood, D. Shinabarger, L. Xiong, and A.S. Mankin The site of action of oxazolidinone antibiotics in living bacteria and in human mitochondria Mol. Cell 26 2007 393 402
67. A.H. Lin, R.W. Murray, T.J. Vidmar, and K.R. Marotti The oxazolidinone eperezolid binds to the 50S ribosomal subunit and competes with binding of chloramphenicol and lincomycin Antimicrob. Agents Chemother. 41 1997 2127 2131
68. Y. Liu, Y. Wang, C. Wu, Z. Shen, S. Schwarz, X.D. Du, L. Dai, W. Zhang, Q. Zhang, and J. Shen First report of the multidrug resistance gene cfr in Enterococcus faecalis of animal origin Antimicrob. Agents Chemother. 56 2012 1650 1654
69. J.B. Locke, M. Hilgers, and K.J. Shaw Mutations in ribosomal protein L3 are associated with oxazolidinone resistance in staphylococci of clinical origin Antimicrob. Agents Chemother. 53 2009 5275 5278
70. J.B. Locke, M. Hilgers, and K.J. Shaw Novel ribosomal mutations in Staphylococcus aureus strains identified through selection with the oxazolidinones linezolid and torezolid (TR-700) Antimicrob. Agents Chemother. 53 2009 5265 5274
71. J.B. Locke, G. Morales, M.G. Hilgers, C.K. Rahawi, S. Jose Picazo, J. Shaw, and K.J.J.L. Stein Elevated linezolid resistance in clinical cfr-positive Staphylococcus aureus isolates is associated with co-occurring mutations in ribosomal protein L3 Antimicrob. Agents Chemother. 54 2010 5352 5355
72. K.S. Long, and B. Vester Resistance to linezolid caused by modifications at its binding site on the ribosome Antimicrob. Agents Chemother. 56 2012 603 612
73. K.S. Long, J. Poehlsgaard, C. Kehrenberg, S. Schwarz, and B. Vester The cfr rRNA methyltransferase confers resistance to phenicols, lincosamides, oxazolidinones, pleuromutilins, and streptogramin A antibiotics Antimicrob. Agents Chemother. 50 2006 2500 2505
74. K.S. Long, C. Munck, T.M. Andersen, M.A. Schaub, S.N. Hobbie, E.C. Bottger, and B. Vester Mutations in 23S rRNA at the peptidyl transferase center and their relationship to linezolid binding and cross-resistance Antimicrob. Agents Chemother. 54 2010 4705 4713
75. S.H. Marshall, C.J. Donskey, R. Hutton-Thomas, R.A. Salata, and L.B. Rice Gene dosage and linezolid resistance in Enterococcus faecium and Enterococcus faecalis Antimicrob. Agents Chemother. 46 2002 3334 3336
76. V.G. Meka, and H.S. Gold Antimicrobial resistance to linezolid Clin. Infect. Dis. 39 2004 1010 1015
77. V.G. Meka, S.K. Pillai, G. Sakoulas, C. Wennersten, L. Venkataraman, P.C. DeGirolami, G.M. Eliopoulos, R.C. Moellering Jr., and H.S. Gold Linezolid resistance in sequential Staphylococcus aureus isolates associated with a T2500A mutation in the 23S rRNA gene and loss of a single copy of rRNA J. Infect. Dis. 190 2004 311 317
78. R.E. Mendes, L.M. Deshpande, M. Castanheira, J. DiPersio, M.A. Saubolle, and R.N. Jones First report of cfr-mediated resistance to linezolid in human staphylococcal clinical isolates recovered in the United States Antimicrob. Agents Chemother. 52 2008 2244 2246
79. R.E. Mendes, M. Sanchez, L.M. Deshpande, M.A. De la Torre, and R.N. Jones Detection of cfr-carrying Staphylococcus spp. isolates recovered from blood cultures in a Spanish hospital during a Phase III clinical trial of tropical omiganan 1% gel versus 10% povidone iodine Abstract 928. 19th ECCMID May 16-19, 2009, Helsinki, Finland 2009
80. R.E. Mendes, L.M. Deshpande, D.J. Farrell, T. Spanu, G. Fadda, and R.N. Jones Assessment of linezolid resistance mechanisms among Staphylococcus epidermidis causing bacteraemia in Rome, Italy J. Antimicrob. Chemother. 65 2010 2329 2335
81. R.E. Mendes, L. Deshpande, E. Rodriguez-Noriega, J.E. Ross, R.N. Jones, and R. Morfin-Otero First report of staphylococcal clinical isolates in Mexico with linezolid resistance caused by cfr: evidence of in vivo cfr mobilization J. Clin. Microbiol. 48 2010 3041 3043
82. R.E. Mendes, L.M. Deshpande, A. Costello, and D.J. Farrell Molecular epidemiology of Staphylococcus epidermidis clinical isolates from USA hospitals Antimicrob. Agents Chemother. 56 2012 4656 4661
83. R.E. Mendes, L.M. Deshpande, J. Kim, D.S. Myers, J.E. Ross, and R.N. Jones Streptococcus sanguinis displaying a cross resistance phenotype to several ribosomal RNA targeting agents J. Clin. Microbiol. 51 2013 2728 2731
84. R.E. Mendes, L.M. Deshpande, H.F. Bonilla, S. Schwarz, M.D. Huband, R.N. Jones, and J.P. Quinn Dissemination of a pSCFS3-like cfr-carrying plasmid in Staphylococcus aureus and Staphylococcus epidermidis clinical isolates recovered from hospitals in Ohio Antimicrob. Agents Chemother. 57 2013 2923 2928
85. R.E. Mendes, R.K. Flamm, P.A. Hogan, J.E. Ross, and R.N. Jones Summary of linezolid activity and resistance mechanisms detected during the 2012 LEADER surveillance program for the United States Antimicrob. Agents Chemother. 58 2014 1243 1247
86. R.E. Mendes, P.A. Hogan, J.M. Streit, R.N. Jones, and R.K. Flamm Zyvox® Annual Appraisal of Potency and Spectrum (ZAAPS) Program: report of linezolid activity over nine years (2004-2012) J. Antimicrob. Chemother. 2014 (in press)
87. K. Michalska, I. Karpiuk, M. Krol, and S. Tyski Recent development of potent analogues of oxazolidinone antibacterial agents Bioorg. Med. Chem. Lett. 21 2013 577 591
88. K. Miller, C.J. Dunsmore, C.W. Fishwick, and I. Chopra Linezolid and tiamulin cross-resistance in Staphylococcus aureus mediated by point mutations in the peptidyl transferase center Antimicrob. Agents Chemother. 52 2008 1737 1742
89. G. Morales, J.J. Picazo, E. Baos, F.J. Candel, A. Arribi, B. Pelaez, R. Andrade, M.A. de la Torre, J. Fereres, and M. Sanchez-Garcia Resistance to linezolid is mediated by the cfr gene in the first report of an outbreak of linezolid-resistant Staphylococcus aureus Clin. Infect. Dis. 50 2010 821 825
90. A.H. Mutnick, D.J. Biedenbach, J.D. Turnidge, and R.N. Jones Spectrum and potency evaluation of a new oxazolidinone, linezolid: report from the SENTRY Antimicrobial Surveillance Program, 1998-2000 Diagn. Microbiol. Infect. Dis. 43 2002 65 73
91. A.H. Mutnick, V. Enne, and R.N. Jones Linezolid resistance since 2001: SENTRY Antimicrobial Surveillance Program Ann. Pharmacother. 37 2003 769 774
92. G.A. Noskin, F. Siddiqui, V. Stosor, D. Hacek, and L.R. Peterson In vitro activities of linezolid against important Gram-positive bacterial pathogens including vancomycin-resistant enterococci Antimicrob. Agents Chemother. 43 1999 2059 2062
93. S.N. Patel, N. Memari, D. Shahinas, B. Toye, F.B. Jamieson, and D.J. Farrell Linezolid resistance in Enterococcus faecium isolated in Ontario, Canada Diagn. Microbiol. Infect. Dis. 77 2013 350 353
94. M.J. Peeters, and J.C. Sarria Clinical characteristics of linezolid-resistant Staphylococcus aureus infections Am. J. Med. Sci. 330 2005 102 104
95. S. Poppe, R. Schaadt, D. Sheehan, D. Sahm, G. Zurenko, and D. Shinabarger Mutation analysis of Staphylococcus aureus isolates demonstrating trailing linezolid (LZD) endpoints in microdilution MIC assays Abstr. A-088. 106th American Society for Microbiology Orlando, FL, USA 2006
96. S. Pournaras, E. Ntokou, O. Zarkotou, K. Ranellou, K. Themeli-Digalaki, C. Stathopoulos, and A. Tsakris Linezolid dependence in Staphylococcus epidermidis bloodstream isolates Emerg. Infect. Dis. 19 2013 129 132
97. M. Pringle, J. Poehlsgaard, B. Vester, and K.S. Long Mutations in ribosomal protein L3 and 23S ribosomal RNA at the peptidyl transferase centre are associated with reduced susceptibility to tiamulin in Brachyspira spp. isolates Mol. Microbiol. 54 2004 1295 1306
98. P. Prokocimer, C. De Anda, E. Fang, P. Mehra, and A. Das Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial J. Am. Med. Assoc. 309 2013 559 569
99. I. Quiles-Melero, R. Gomez-Gil, M.P. Romero-Gomez, A.M. Sanchez-Diaz, M. de Pablos, J. Garcia-Rodriguez, A. Gutierrez, and J. Mingorance Mechanisms of linezolid resistance among staphylococci in a tertiary hospital J. Clin. Microbiol. 51 2013 998 1001
100. J.E. Ross, T.R. Anderegg, H.S. Sader, T.R. Fritsche, and R.N. Jones Trends in linezolid susceptibility patterns in 2002: report from the worldwide Zyvox Annual Appraisal of Potency and Spectrum Program Diagn. Microbiol. Infect. Dis. 52 2005 53 58
101. J.E. Ross, T.R. Fritsche, H.S. Sader, and R.N. Jones Oxazolidinone susceptibility patterns for 2005: international report from the Zyvox® Annual Appraisal of Potency and Spectrum Study Int. J. Antimicrob. Agents 29 2007 295 301
102. J.E. Ross, R.N. Jones, P.A. Hogan, and D.J. Sheehan Initial occurrences of linezolid (LZD) resistance (R) from the Zyvox Annual Appraisal of Potency and Spectrum (ZAAPS) Program (Europe, Latin, America, Asia Pacific) Abstract C2-865. 47th ICAAC September 17-20, 2007, Chicago, IL, USA 2007
103. J.E. Ross, U. Utsuki, I. Fumiaki, I. Kobayashi, R.N. Jones, and P.A. Hogan Zyvox® Annual Appraisal of Potency and Spectrum (ZAAPS) Program 2008 (Europe, Latin America, Canada, Asia Pacific): linezolid global in vitro susceptibility analyses Abstracts A-078. 109th ASM, May 17-21, 2009 Philadelphia, PA, USA 2009
104. M.J. Rybak, D.M. Cappelletty, T. Moldovan, J.R. Aeschlimann, and G.W. Kaatz Comparative in vitro activities and postantibiotic effects of the oxazolidinone compounds eperezolid (PNU-100592) and linezolid (PNU-100766) versus vancomycin against Staphylococcus aureus, coagulase-negative staphylococci, Enterococcus faecalis, and Enterococcus faecium Antimicrob. Agents Chemother. 42 1998 721 724
105. M.J. Rybak, E. Hershberger, T. Moldovan, and R.G. Grucz In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against Staphylococci and Enterococci, including vancomycin-intermediate and -resistant strains Antimicrob. Agents Chemother. 44 2000 1062 1066
106. S. Schwarz, C. Werckenthin, and C. Kehrenberg Identification of a plasmid-borne chloramphenicol-florfenicol resistance gene in Staphylococcus sciuri Antimicrob. Agents Chemother. 44 2000 2530 2533
107. K.J. Shaw, and M.R. Barbachyn The oxazolidinones: past, present, and future Ann. N.Y. Acad. Sci. 1241 2011 48 70
108. J. Shen, Y. Wang, and S. Schwarz Presence and dissemination of the multiresistance gene cfr in Gram-positive and Gram-negative bacteria J. Antimicrob. Chemother. 68 2013 1697 1706
109. D.L. Shinabarger, K.R. Marotti, R.W. Murray, A.H. Lin, E.P. Melchior, S.M. Swaney, D.S. Dunyak, W.F. Demyan, and J.M. Buysse Mechanism of action of oxazolidinones: effects of linezolid and eperezolid on translation reactions Antimicrob. Agents Chemother. 41 1997 2132 2136
110. A.C. Shore, O.M. Brennan, R. Ehricht, S. Monecke, S. Schwarz, P. Slickers, and D.C. Coleman Identification and characterization of the multidrug resistance gene cfr in a Panton-Valentine leukocidin-positive sequence type 8 methicillin-resistant Staphylococcus aureus IVa (USA300) isolate Antimicrob. Agents Chemother. 54 2010 4978 4984
111. J.M. Sierra, M. Ortega, C. Tarrago, C. Albet, J. Vila, J. Terencio, and A. Guglietta Decreased linezolid uptake in an in vitro-selected linezolid-resistant Staphylococcus epidermidis mutant J. Antimicrob. Chemother. 64 2009 990 992
112. J.M. Sierra, M. Camoez, F. Tubau, O. Gasch, M. Pujol, R. Martin, and M.A. Dominguez Low prevalence of Cfr-mediated linezolid resistance among methicillin-resistant Staphylococcus aureus in a Spanish hospital: case report on linezolid resistance acquired during linezolid therapy PLoS ONE 8 2013 e59215
113. L.K. Smith, and A.S. Mankin Transcriptional and translational control of the mlr operon, which confers resistance to seven classes of protein synthesis inhibitors Antimicrob. Agents Chemother. 52 2008 1703 1712
114. S. Stefani, D. Bongiorno, G. Mongelli, and F. Campanile Linezolid resistance in staphylococci Pharmaceuticals 3 2010 1 18
115. F.C. Tenover, P.P. Williams, S. Stocker, A. Thompson, L.A. Clark, B. Limbago, R.B. Carey, S.M. Poppe, D. Shinabarger, and J.E. McGowan Jr. Accuracy of six antimicrobial susceptibility methods for testing linezolid against staphylococci and enterococci J. Clin. Microbiol. 45 2007 2917 2922
116. S.M. Toh, L. Xiong, C.A. Arias, M.V. Villegas, K. Lolans, J. Quinn, and A.S. Mankin Acquisition of a natural resistance gene renders a clinical strain of methicillin-resistant Staphylococcus aureus resistant to the synthetic antibiotic linezolid Mol. Microbiol. 64 2007 1506 1514
117. S.M. Toh, L. Xiong, T. Bae, and A.S. Mankin The methyltransferase YfgB/RlmN is responsible for modification of adenosine 2503 in 23S rRNA RNA 14 2008 98 106
118. A. Tsakris, S.K. Pillai, H.S. Gold, C. Thauvin-Eliopoulos, L. Venkataraman, C. Wennersten, R.C. Moellering Jr., and G.M. Eliopoulos Persistence of rRNA operon mutated copies and rapid re-emergence of linezolid resistance in Staphylococcus aureus J. Antimicrob. Chemother. 60 2007 649 651
119. S. Tsiodras, H.S. Gold, G. Sakoulas, G.M. Eliopoulos, C. Wennersten, L. Venkataraman, R.C. Moellering, and M.J. Ferraro Linezolid resistance in a clinical isolate of Staphylococcus aureus Lancet 358 2001 207 208
120. C. von Eiff, and G. Peters Comparative in-vitro activities of moxifloxacin, trovafloxacin, quinupristin/dalfopristin and linezolid against staphylococci J. Antimicrob. Chemother. 43 1999 569 573
121. Y. Wang, Y. Wang, C.M. Wu, S. Schwarz, Z. Shen, W. Zhang, Q. Zhang, and J.Z. Shen Detection of the staphylococcal multiresistance gene cfr in Proteus vulgaris of food animal origin J. Antimicrob. Chemother. 66 2011 2521 2526
122. Y. Wang, Y. Wang, S. Schwarz, Z. Shen, N. Zhou, J. Lin, C. Wu, and J. Shen Detection of the staphylococcal multiresistance gene cfr in Macrococcus caseolyticus and Jeotgalicoccus pinnipedialis J. Antimicrob. Chemother. 67 2012 1824 1827
123. Y. Wang, S. Schwarz, Z. Shen, W. Zhang, J. Qi, Y. Liu, T. He, J. Shen, and C. Wu Co-location of the multiresistance gene cfr and the novel streptomycin resistance gene aadY on a small plasmid in a porcine Bacillus strain J. Antimicrob. Chemother. 67 2012 1547 1549
124. Y. Wang, D. Li, L. Song, Y. Liu, T. He, H. Liu, C. Wu, S. Schwarz, and J. Shen First report of the multiresistance gene cfr in Streptococcus suis Antimicrob. Agents Chemother. 57 2013 4061 4063
125. P. Wilson, J.A. Andrews, R. Charlesworth, R. Walesby, M. Singer, D.J. Farrell, and M. Robbins Linezolid resistance in clinical isolates of Staphylococcus aureus J. Antimicrob. Chemother. 51 2003 186 188
126. R. Wise, J.M. Andrews, F.J. Boswell, and J.P. Ashby The in vitro activity of linezolid (U-100766) and tentative breakpoints J. Antimicrob. Chemother. 42 1998 721 728
127. N. Wolter, A.M. Smith, D.J. Farrell, W. Schaffner, M. Moore, C.G. Whitney, J.H. Jorgensen, and K.P. Klugman Novel mechanism of resistance to oxazolidinones, macrolides, and chloramphenicol in ribosomal protein L4 of the pneumococcus Antimicrob. Agents Chemother. 49 2005 3554 3557
128. A. Wong, S.P. Reddy, D.S. Smyth, M.E. Aguero-Rosenfeld, G. Sakoulas, and D.A. Robinson Polyphyletic emergence of linezolid-resistant staphylococci in the United States Antimicrob. Agents Chemother. 54 2010 742 748
129. S. Worth, M.E. Erwin, and R.N. Jones Quality control guidelines for amoxicillin, amoxicillin-clavulanate, azithromycin, piperacillin-tazobactam, roxithromycin, ticarcillin, ticarcillin-clavulanate, trovafloxacin (CP 99,219), U-100592, and U-100766 for various National Committee for Clinical Laboratory Standards susceptibility testing methods. Results from multicenter trials Diagn. Microbiol. Infect. Dis. 24 1996 87 91
130. F. Yan, J.M. LaMarre, R. Rohrich, J. Wiesner, H. Jomaa, A.S. Mankin, and D.G. Fujimori RlmN and Cfr are radical SAM enzymes involved in methylation of ribosomal RNA J. Am. Chem. Soc. 132 2010 3953 3964
131. W.J. Zhang, C.M. Wu, Y. Wang, Z.Q. Shen, L. Dai, J. Han, S.L. Foley, J.Z. Shen, and Q. Zhang The new genetic environment of cfr on plasmid pBS-02 in a Bacillus strain J. Antimicrob. Chemother. 66 2011 1174 1175
132. W.J. Zhang, X.R. Xu, S. Schwarz, X.M. Wang, L. Dai, H.J. Zheng, and S. Liu Characterization of the IncA/C plasmid pSCEC2 from Escherichia coli of swine origin that harbours the multiresistance gene cfr J. Antimicrob. Chemother. 69 2014 385 389
133. G.E. Zurenko, B.H. Yagi, R.D. Schaadt, J.W. Allison, J.O. Kilburn, S.E.
134. Zyvox Zyvox Package Insert 2010 available at http://www.pfizer.com/ products/rx/rx-product-zyvox.jsp (accessed January 2013)